Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Information only

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,224 result(s) found for: Information only. Displaying page 37 of 112.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next» Last»»
    EudraCT Number: 2007-004033-42 Sponsor Protocol Number: MKI102428 Start Date*: 2007-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD).
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) EE (Completed) FI (Completed) LT (Completed) SI (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004990-34 Sponsor Protocol Number: MK-0431-845 Start Date*: 2016-05-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared with the Withdrawal of Sitagliptin...
    Medical condition: Type 2 Diabetes Mellitus (T2DM)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) LV (Completed) CZ (Completed) ES (Completed) DK (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003308-38 Sponsor Protocol Number: V114-031 Start Date*: 2019-02-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU - LINK)
    Medical condition: Pneumoccal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-003716-47 Sponsor Protocol Number: GCT1042-01 Start Date*: 2019-07-02
    Sponsor Name:Genmab A/S
    Full Title: A first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety and anti-tumor activity of GEN1042 in subjects with malignant solid tumors
    Medical condition: Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer (CRC) who are not anymore candidates for ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Trial now transitioned) ES (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-003820-37 Sponsor Protocol Number: IGIT-008 Start Date*: 2005-02-10
    Sponsor Name:Bracco Imaging Spa
    Full Title: A multicentre study to evaluate the Contibution of SonoVue® and CnTI technology (Contrast Tuned Imaging) to a correct classification of Adnexal Masses as benign or malignant
    Medical condition: COMPLEX ADNEXAL MASS IN PELVIS
    Disease: Version SOC Term Classification Code Term Level
    10029104 SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011428-79 Sponsor Protocol Number: C14008 Start Date*: 2012-10-09
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Perito...
    Medical condition: Adenocarcinoma of the breast (Phase 1 only). Ovarian Cancer, defined to include recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (Phases 1 and 2).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058448 Peritoneal adenocarcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006173 Breast adenocarcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003154-40 Sponsor Protocol Number: MK-4305-061 Start Date*: 2017-01-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects with Alzheimer’s Disease
    Medical condition: Insomnia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10022437 Insomnia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001323-21 Sponsor Protocol Number: VX11-950-114 Start Date*: 2012-01-31
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC...
    Medical condition: chronic hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003661-26 Sponsor Protocol Number: HX-02-PEP Start Date*: 2017-02-16
    Sponsor Name:Haemostatix Ltd
    Full Title: A controlled, randomized, multi-centre, double blind, phase II study to evaluate efficacy and safety of topical PeproStat in intraoperative surgical haemostasis
    Medical condition: To achieve haemostasis when bleeding cannot be controlled by conventional methods alone, such as manual pressure, cauterization, or sutures; or are inappropriate.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10053001 Surgical haemostasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023584-17 Sponsor Protocol Number: RAS-AZIC Start Date*: 2012-08-31
    Sponsor Name:Universität Leipzig
    Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent...
    Medical condition: acute myeloid leukeamia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004341-27 Sponsor Protocol Number: MK-3641-008 Start Date*: 2016-01-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a Histo...
    Medical condition: Rhinoconjunctivitis due to ragweed allergy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) HR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003561-34 Sponsor Protocol Number: PCYC-1121-CA Start Date*: 2014-01-07
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma
    Medical condition: Relapsed or refractory marginal zone lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003464-22 Sponsor Protocol Number: CEFTOFBN3004 Start Date*: 2007-10-05
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Noninferiority, Multicenter Study of Ceftobiprole Medocaril Versus Cefepime With or Without Vancomycin in the Treatment of Subjects Wi...
    Medical condition: Subjects 18 years of age or older with fever and neutropenia after chemotherapy for cancer, who require i.v. therapy for treatment of fever and neutropenia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002208-26 Sponsor Protocol Number: MK-8342B-062 Start Date*: 2015-10-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.
    Full Title: A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17β-estradiol) vaginal ring and the levonorgestrel-...
    Medical condition: Contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed) SE (Completed) DE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) HU (Completed) PL (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002388-13 Sponsor Protocol Number: AZA-JMML-001 Start Date*: 2015-02-20
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics, safety and activity of azacitidine and to compare azacitidine to historical controls in pediatric subjec...
    Medical condition: newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054439 Juvenile chronic myelomonocytic leukemia LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023249 Juvenile chronic myelomonocytic leukaemia PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IE (Completed) AT (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) DK (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001067-36 Sponsor Protocol Number: 18588 Start Date*: 2016-11-21
    Sponsor Name:Bayer AG
    Full Title: A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosp...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005209-23 Sponsor Protocol Number: CA163139 Start Date*: 2008-03-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/...
    Medical condition: BREAST CANCER, FIRST LINE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Gender: Female
    Trial protocol: FR (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004140-23 Sponsor Protocol Number: 27298 Start Date*: 2007-06-06
    Sponsor Name:Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa anta...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BE (Completed) BG (Completed) PT (Completed) ES (Completed) GR (Completed) IT (Completed) NL (Completed) SE (Completed) FI (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001823-30 Sponsor Protocol Number: 043/SI Start Date*: 2017-06-12
    Sponsor Name:SIFI SpA
    Full Title: Randomized, Assessor-Masked, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Comparison with 0.02% ...
    Medical condition: Acanthamoeba keratitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10069408 Acanthamoeba keratitis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002193-40 Sponsor Protocol Number: DT-001-R-004 Start Date*: 2018-04-04
    Sponsor Name:Afyx Therapeutics A/S
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate when Administered Intra-orally Twice Daily in...
    Medical condition: Oral Lichen Planus (OLP). OLP is a common, chronic mucosal disease associated with a cell-mediated immunological dysfunction and characterized by exacerbations of inflammation, which can lead to ul...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10030983 Oral lichen planus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 08:52:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA